AU2011204483B2 - EV576 for use in the treatment of viral infections of the respiratory tract - Google Patents
EV576 for use in the treatment of viral infections of the respiratory tract Download PDFInfo
- Publication number
- AU2011204483B2 AU2011204483B2 AU2011204483A AU2011204483A AU2011204483B2 AU 2011204483 B2 AU2011204483 B2 AU 2011204483B2 AU 2011204483 A AU2011204483 A AU 2011204483A AU 2011204483 A AU2011204483 A AU 2011204483A AU 2011204483 B2 AU2011204483 B2 AU 2011204483B2
- Authority
- AU
- Australia
- Prior art keywords
- agent
- protein
- complement
- use according
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 35
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 34
- 230000009385 viral infection Effects 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 27
- 206010022000 influenza Diseases 0.000 claims abstract description 14
- 208000037797 influenza A Diseases 0.000 claims abstract description 11
- 206010064097 avian influenza Diseases 0.000 claims abstract description 7
- 208000002979 Influenza in Birds Diseases 0.000 claims abstract description 5
- 241000282898 Sus scrofa Species 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 86
- 239000003795 chemical substances by application Substances 0.000 claims description 62
- 102100031506 Complement C5 Human genes 0.000 claims description 30
- 230000024203 complement activation Effects 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 13
- 102000004856 Lectins Human genes 0.000 claims description 11
- 108090001090 Lectins Proteins 0.000 claims description 11
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 11
- 239000002523 lectin Substances 0.000 claims description 11
- 201000004193 respiratory failure Diseases 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 10
- 108010028773 Complement C5 Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 claims description 7
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 claims description 7
- 108010078546 Complement C5a Proteins 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 150000002066 eicosanoids Chemical class 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 241000238421 Arthropoda Species 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 description 79
- 239000003981 vehicle Substances 0.000 description 29
- 238000010172 mouse model Methods 0.000 description 24
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 22
- 201000010740 swine influenza Diseases 0.000 description 22
- 241000700605 Viruses Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 210000000440 neutrophil Anatomy 0.000 description 19
- 230000009467 reduction Effects 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000004154 complement system Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229960003752 oseltamivir Drugs 0.000 description 6
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 4
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 4
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000238876 Acari Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108050006654 Lipocalin Proteins 0.000 description 3
- 102000019298 Lipocalin Human genes 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108700006906 tick rEV131 Proteins 0.000 description 3
- 108010089414 Anaphylatoxins Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010078596 Complement C5b Proteins 0.000 description 2
- 241000258924 Ctenocephalides felis Species 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- -1 IL- IP Proteins 0.000 description 2
- 241000238890 Ornithodoros moubata Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LMRJHNFECNKDKH-UHFFFAOYSA-N 4-(trifluoromethyl)nicotinic acid Chemical compound OC(=O)C1=CN=CC=C1C(F)(F)F LMRJHNFECNKDKH-UHFFFAOYSA-N 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 241000238682 Amblyomma americanum Species 0.000 description 1
- 241001480735 Amblyomma cajennense Species 0.000 description 1
- 241001480736 Amblyomma hebraeum Species 0.000 description 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 241001480752 Argas persicus Species 0.000 description 1
- 241001480754 Argas reflexus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 241000256057 Culex quinquefasciatus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241001480819 Dermacentor andersoni Species 0.000 description 1
- 241000227772 Dermacentor marginatus Species 0.000 description 1
- 241000577477 Dermacentor reticulatus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 241000257324 Glossina <genus> Species 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000233007 Haemaphysalis inermis Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100365658 Homo sapiens SCGB3A1 gene Proteins 0.000 description 1
- 101000823955 Homo sapiens Serine palmitoyltransferase 1 Proteins 0.000 description 1
- 241000750137 Hyalomma anatolicum anatolicum Species 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 241001480847 Ixodes persulcatus Species 0.000 description 1
- 241001480843 Ixodes ricinus Species 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000092202 Ornithodoros erraticus Species 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 241000242594 Platyhelminthes Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241001480837 Rhipicephalus annulatus Species 0.000 description 1
- 241001481704 Rhipicephalus appendiculatus Species 0.000 description 1
- 241000949016 Rhipicephalus bursa Species 0.000 description 1
- 241000864246 Rhipicephalus decoloratus Species 0.000 description 1
- 241000238680 Rhipicephalus microplus Species 0.000 description 1
- 240000003516 Rumex sanguineus Species 0.000 description 1
- 102100022068 Serine palmitoyltransferase 1 Human genes 0.000 description 1
- 241000256103 Simuliidae Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000255628 Tabanidae Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 101100357018 Trypanosoma brucei brucei RNR2 gene Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000013764 eosinophil chemotaxis Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000032027 negative regulation of neutrophil apoptotic process Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016203058A AU2016203058B2 (en) | 2010-01-08 | 2016-05-11 | EV576 for use in the treatment of viral infections of the respiratory tract |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1000318.4A GB201000318D0 (en) | 2010-01-08 | 2010-01-08 | Method of treatment |
| GB1000318.4 | 2010-01-08 | ||
| GB1005071.4 | 2010-03-25 | ||
| GBGB1005071.4A GB201005071D0 (en) | 2010-03-25 | 2010-03-25 | Method of treatment |
| PCT/GB2011/000022 WO2011083317A1 (en) | 2010-01-08 | 2011-01-10 | Ev576 for use in the treatment of viral infections of the respiratory tract |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203058A Division AU2016203058B2 (en) | 2010-01-08 | 2016-05-11 | EV576 for use in the treatment of viral infections of the respiratory tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011204483A1 AU2011204483A1 (en) | 2012-07-12 |
| AU2011204483B2 true AU2011204483B2 (en) | 2016-02-11 |
Family
ID=44305222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011204483A Active AU2011204483B2 (en) | 2010-01-08 | 2011-01-10 | EV576 for use in the treatment of viral infections of the respiratory tract |
| AU2016203058A Active AU2016203058B2 (en) | 2010-01-08 | 2016-05-11 | EV576 for use in the treatment of viral infections of the respiratory tract |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203058A Active AU2016203058B2 (en) | 2010-01-08 | 2016-05-11 | EV576 for use in the treatment of viral infections of the respiratory tract |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20120283167A1 (https=) |
| EP (1) | EP2521562B1 (https=) |
| JP (1) | JP5840623B2 (https=) |
| CN (1) | CN102762223B (https=) |
| AU (2) | AU2011204483B2 (https=) |
| CA (1) | CA2785612C (https=) |
| NZ (1) | NZ601018A (https=) |
| PL (1) | PL2521562T3 (https=) |
| WO (1) | WO2011083317A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3119802B1 (en) * | 2014-03-20 | 2019-12-04 | InflaRx GmbH | Inhibitors of c5a for the treatment of viral pneumonia |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US20220047673A1 (en) * | 2018-09-10 | 2022-02-17 | Volution Immuno Pharmaceuticals Sa | Coversin for Use in the Treatment of Rheumatic Diseases |
| GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US12097222B2 (en) | 2019-06-06 | 2024-09-24 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| WO2020247610A1 (en) | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
| JP2023503776A (ja) | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230218571A1 (en) * | 2020-04-01 | 2023-07-13 | Thiogenesis Therapeutics, Inc. | Cysteamine precursor compounds for the treatment of betacoronavirus infections |
| EP4146168A4 (en) * | 2020-05-08 | 2024-06-12 | Kodiak Sciences Inc. | USE OF IL-6 ANTIBODIES AND VEGF TRAPS AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070141573A1 (en) * | 2003-06-02 | 2007-06-21 | Nunn Miles A | Complement inhibitors |
| WO2008029169A2 (en) * | 2006-09-08 | 2008-03-13 | Varleigh Limited | Method of treating respiratory disorders |
| WO2009098454A2 (en) * | 2008-02-05 | 2009-08-13 | Natural Environment Research Council | Treatment of diseases and conditions mediated by eicosanoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017099A1 (en) | 1992-02-27 | 1993-09-02 | Merck & Co., Inc. | Protein for inhibiting collagen-stimulated platelet aggregation |
| US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007117241A1 (en) * | 2006-04-12 | 2007-10-18 | Biocryst Pharmaceuticals, Inc. | Intramuscular antiviral treatments |
| US7274999B1 (en) * | 2006-03-10 | 2007-09-25 | Atmel Corporation | Brownout detector system and method |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
-
2011
- 2011-01-10 AU AU2011204483A patent/AU2011204483B2/en active Active
- 2011-01-10 JP JP2012547546A patent/JP5840623B2/ja active Active
- 2011-01-10 PL PL11700973T patent/PL2521562T3/pl unknown
- 2011-01-10 NZ NZ601018A patent/NZ601018A/xx not_active IP Right Cessation
- 2011-01-10 US US13/521,011 patent/US20120283167A1/en not_active Abandoned
- 2011-01-10 EP EP11700973.8A patent/EP2521562B1/en active Active
- 2011-01-10 CN CN201180005464.6A patent/CN102762223B/zh active Active
- 2011-01-10 CA CA2785612A patent/CA2785612C/en active Active
- 2011-01-10 WO PCT/GB2011/000022 patent/WO2011083317A1/en not_active Ceased
-
2015
- 2015-01-02 US US14/588,616 patent/US9522171B2/en active Active
-
2016
- 2016-05-11 AU AU2016203058A patent/AU2016203058B2/en active Active
- 2016-07-22 US US15/217,601 patent/US20170065677A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,737 patent/US20200155646A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070141573A1 (en) * | 2003-06-02 | 2007-06-21 | Nunn Miles A | Complement inhibitors |
| WO2008029169A2 (en) * | 2006-09-08 | 2008-03-13 | Varleigh Limited | Method of treating respiratory disorders |
| WO2009098454A2 (en) * | 2008-02-05 | 2009-08-13 | Natural Environment Research Council | Treatment of diseases and conditions mediated by eicosanoids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102762223A (zh) | 2012-10-31 |
| US20200155646A1 (en) | 2020-05-21 |
| JP2013516450A (ja) | 2013-05-13 |
| AU2016203058A1 (en) | 2016-06-02 |
| AU2016203058B2 (en) | 2018-01-18 |
| CA2785612C (en) | 2019-09-10 |
| EP2521562B1 (en) | 2019-09-18 |
| US9522171B2 (en) | 2016-12-20 |
| US20120283167A1 (en) | 2012-11-08 |
| EP2521562A1 (en) | 2012-11-14 |
| US20170065677A1 (en) | 2017-03-09 |
| AU2011204483A1 (en) | 2012-07-12 |
| CA2785612A1 (en) | 2011-07-14 |
| JP5840623B2 (ja) | 2016-01-06 |
| US20150196619A1 (en) | 2015-07-16 |
| WO2011083317A1 (en) | 2011-07-14 |
| PL2521562T3 (pl) | 2020-04-30 |
| CN102762223B (zh) | 2014-09-03 |
| NZ601018A (en) | 2013-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011204483B2 (en) | EV576 for use in the treatment of viral infections of the respiratory tract | |
| US20210244792A1 (en) | Method of Treating Respiratory Disorders | |
| AU2007293239B2 (en) | Method of treating peripheral nerve disorders | |
| US20200282018A1 (en) | Method of Treating Myasthenia Gravis | |
| DK2061501T3 (en) | METHOD OF TREATING RESPIRATORY DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: VOLUTION IMMUNO PHARMACEUTICALS SA Free format text: FORMER APPLICANT(S): VARLEIGH IMMUNO PHARMACEUTICALS (VIP) LTD |
|
| FGA | Letters patent sealed or granted (standard patent) |